Avicanna Inc has seen some movement in its stock price, reflecting recent developments and market sentiment.
Avicanna Inc (AVCN.TO) experienced a modest increase in its stock price this week, closing at C$0.13, which is a 3.85% rise from the previous day. However, the stock is still down 38.64% year-to-date. Let’s take a closer look at Avicanna's recent performance and market activity.
Investor takeaway: Investors in Avicanna should consider the company's recent product launches and executive changes while keeping an eye on its overall market performance and financial metrics.
Advertisement
Avicanna Inc
AVCN.TO
AVCN.TO
Avicanna Inc
WealthAwesomeAdvertisement
Market cap
$16.98M
52W high
$0.30
52W low
$0.10
1W change
+0.00%
Beta
0.33
Analyst Price Targets
Based on analyst covering AVCN
Wall Street analysts forecast AVCN stock price to rise 418.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+418.5% Upside
Current Price
C$0.14
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AVCN's historical volatility
30-Day Vol
69.6%
Annualized
90-Day Vol
65.3%
Annualized
Trend (90d)
+15.9%
Annualized drift
90d Mean
C$0.14
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.14 | C$0.11 – C$0.17 |
| 60 trading days | C$0.14 | C$0.10 – C$0.20 |
| 90 trading days | C$0.14 | C$0.09 – C$0.22 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Avicanna’s stock is currently priced at C$0.13, with a 52-week range of C$0.10 to C$0.30.
The stock's closing price represents 17% of its 52-week range, indicating potential volatility and investor uncertainty.
Bull case
The launch of Avicanna's QUIX™ rapid-onset medical cannabis portfolio could position the company well in the growing medical cannabis market, potentially driving revenue growth.
Bear case
The company's ongoing financial losses and a significant year-to-date decline in stock price may raise concerns for investors about its long-term viability.
Recent Price Action
Avicanna Inc's stock closed at C$0.13 this week, representing a 3.85% increase from the previous day. Over the past month, the stock has gained 12.50%, although it remains significantly down 38.64% year-to-date. The latest trading volume was 45,000 shares, which is below the 20-day average volume of 55,684 shares, indicating a current volume ratio of 0.84x.
Advertisement
Company Developments
Recent headlines highlight Avicanna's strategic moves, including the introduction of the QUIX™ rapid-onset medical cannabis portfolio, aimed at enhancing its product offerings in the competitive medical cannabis market. Additionally, the company appointed Nick Hilborn as its new Chief Financial Officer to strengthen its financial leadership. These developments may help Avicanna better navigate the evolving landscape of the health care sector.
Technical Picture
From a technical standpoint, Avicanna's stock is currently trading at its 50-day moving average of C$0.13, showing a slight increase of 3.9% compared to the recent price. However, it is trading below its 200-day moving average of C$0.17, which is down 25.2% from the current price. The stock's beta of 0.33 suggests lower volatility compared to the broader market, which may appeal to risk-averse investors.
Market Sentiment
Despite the recent uptick in stock price, Avicanna's market cap stands at approximately C$16.98 million, with a negative profit margin of -12.1% and a return on equity of -26.5%. Analysts remain optimistic, with an average target price of C$0.70, suggesting significant upside potential from the current price, but reaching this target reflects a high degree of risk.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
